Comparative Study of Paliperidone ER Tablets and Risperidone Tablets in Treatment of Childhood and Adolescents First Episode Schizophrenia

Lei Jie Peng; Yang Li; Luo Cheng; Zhang Ti Yuan; Lv Xin; Li Sheng Qiao; Lin Hai Bo

Article Contents

Article Navigation > Journal of Kunming Medical University > 2017 > 38(09): 92-95

Lei Jie Peng , Yang Li , Luo Cheng , Zhang Ti Yuan , Lv Xin , Li Sheng Qiao , Lin Hai Bo . Comparative Study of Paliperidone ER Tablets and Risperidone Tablets in Treatment of Childhood and Adolescents First Episode Schizophrenia[J]. Journal of Kunming Medical University, 2017, 38(09): 92-95.

Citation:

Lei Jie Peng , Yang Li , Luo Cheng , Zhang Ti Yuan , Lv Xin , Li Sheng Qiao , Lin Hai Bo . Comparative Study of Paliperidone ER Tablets and Risperidone Tablets in Treatment of Childhood and Adolescents First Episode Schizophrenia[J]. Journal of Kunming Medical University, 2017, 38(09): 92-95.

Citation:

Lei Jie Peng , Yang Li , Luo Cheng , Zhang Ti Yuan , Lv Xin , Li Sheng Qiao , Lin Hai Bo . Comparative Study of Paliperidone ER Tablets and Risperidone Tablets in Treatment of Childhood and Adolescents First Episode Schizophrenia[J]. Journal of Kunming Medical University, 2017, 38(09): 92-95.

PDF( 139 KB)

Comparative Study of Paliperidone ER Tablets and Risperidone Tablets in Treatment of Childhood and Adolescents First Episode Schizophrenia

Funds:

基金：云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目 (20150121);

Received Date: 2017-04-17

Abstract

Abstract

Objective To explore the efficacy and safety of Paliperidone extended-release tablets (Paliperidone ER) and Risperidone tablets in treatment of childhood and adolescents first episode schizophrenia.Methods 66 children with first-episode schizophrenia were randomly divided into Paliperidone group (n=33, treated with Paliperidone ER) and Risperidone group (n=33, orally took Risperidone tablets) and treated for 8 weeks.The efficacy and adverse reactions were assessed with positive and negative syndrome scale (PANSS) and treatment emergent symptom scale (TESS) before and 1, 2, 4, 8 weeks after the treatment.Results The total score and the factor scores of PANSS in the two groups were significantly decreased after the treatment (P<0.05 or P<0.01) .At the first weekend, the score of PANSS was significantly lower in Paliperidone group than that in the Risperidone group (P<0.05) .The other factors had no significant differences (P>0.05) .In comparison of the adverse reactions between the two groups, the adverse drug reaction incidence of Paliperidone group was lower than that of Risperidone group (P <0.01) .Conclusions Paliperidone ER in the treatment of childhood and adolescents first episode schizophrenia has a rapid effect, less adverse reactions, and a high safety.
- Aliperidone ER,
- Risperidone tablets,
- Schizophrenia

FullText(HTML)

References(17)

References

[1]	[1]FRAZIER J A, GIULIANO A J, JOHNSON J L, et al.Neurocognitive outcomes in the treatment of early-onset schizophrenia spectrum disorders study[J].Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51 (5) :496-505.[1]FRAZIER J A, GIULIANO A J, JOHNSON J L, et al.Neurocognitive outcomes in the treatment of early-onset schizophrenia spectrum disorders study[J].Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51 (5) :496-505.
[2]张鸿燕, 郝晓楠, 王雪芹, 等.帕利哌酮缓释片治疗非急性期精神分裂症疗效及安全性的开放性研究[J].中华精神科杂志, 2012, 45 (1) :20-24.[2]张鸿燕, 郝晓楠, 王雪芹, 等.帕利哌酮缓释片治疗非急性期精神分裂症疗效及安全性的开放性研究[J].中华精神科杂志, 2012, 45 (1) :20-24.
[3]张鸿燕, 李华芳, 王刚, 等.帕利哌酮缓释片治疗急性精神分裂症疗效及安全性的对照研究[J].中华精神科杂志, 2009, 42 (3) :153-157.[3]张鸿燕, 李华芳, 王刚, 等.帕利哌酮缓释片治疗急性精神分裂症疗效及安全性的对照研究[J].中华精神科杂志, 2009, 42 (3) :153-157.
[4]	[4]HAAS M, UNIS A S, ARMENTEROS J, et al.A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia[J].Journal of child and adolescent psychopharmacology, 2009, 19 (6) :611-621.[4]HAAS M, UNIS A S, ARMENTEROS J, et al.A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia[J].Journal of child and adolescent psychopharmacology, 2009, 19 (6) :611-621.
[5]陈云芳, 张立勇.利培酮治疗少年儿童首发精神分裂症的疗效及安全性观察[J].中国神经精神疾病杂志, 2005, 31 (5) :395-396.[5]陈云芳, 张立勇.利培酮治疗少年儿童首发精神分裂症的疗效及安全性观察[J].中国神经精神疾病杂志, 2005, 31 (5) :395-396.
[6]范肖冬, 汪向东, 于欣, 等译.ICD-10精神与行为障碍分类[M].北京:人民卫生出版社, 1993:70-79.[6]范肖冬, 汪向东, 于欣, 等译.ICD-10精神与行为障碍分类[M].北京:人民卫生出版社, 1993:70-79.
[7] 苏林雁.儿童精神医学[M].长沙:湖南科学技术出版社, 2014:377.[7]苏林雁.儿童精神医学[M].长沙:湖南科学技术出版社, 2014:377.
[8]中国精神障碍分类与诊断标准·第3版/中华医学会精神科分会编[M].济南:山东科学技术出版社, 2001:75-78.[8]中国精神障碍分类与诊断标准·第3版/中华医学会精神科分会编[M].济南:山东科学技术出版社, 2001:75-78.
[9]李淑芬, 李素水, 王克强.国外儿童青少年精神分裂症治疗研究进展[J].中国健康心理学杂志, 2011, 19 (5) :626-628.[9]李淑芬, 李素水, 王克强.国外儿童青少年精神分裂症治疗研究进展[J].中国健康心理学杂志, 2011, 19 (5) :626-628.
[10]	[10]FOWLER J A, BETTINGER T L, ARGO T R.Paliperidone extended-release tablets for the acute and maintenance treatment of Schizophrenia[J].Clin Ther, 2008, 30 (2) :231-248.[10]FOWLER J A, BETTINGER T L, ARGO T R.Paliperidone extended-release tablets for the acute and maintenance treatment of Schizophrenia[J].Clin Ther, 2008, 30 (2) :231-248.
[11]	[11]MICHAEL D, ROBIN E, MICHELLE K, et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER) results of a 6-week, randomized, placebo-controlled study[J].Schizophrenia, 2007, 93 (1) :117-130.[11]MICHAEL D, ROBIN E, MICHELLE K, et al.Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER) results of a 6-week, randomized, placebo-controlled study[J].Schizophrenia, 2007, 93 (1) :117-130.
[12]舒良, 蔡焯基, 吉中孚, 等.帕利哌酮缓释片临床用药指导意见[J].中国新药杂志, 2011, 20 (16) :1514-1521.[12]舒良, 蔡焯基, 吉中孚, 等.帕利哌酮缓释片临床用药指导意见[J].中国新药杂志, 2011, 20 (16) :1514-1521.
[13]姜雪晶.帕利哌酮缓释片对精神分裂症疗效及安全性的对照研究[J].世界最新医学信息文摘, 2015, 15 (69) :3-4.[13]姜雪晶.帕利哌酮缓释片对精神分裂症疗效及安全性的对照研究[J].世界最新医学信息文摘, 2015, 15 (69) :3-4.
[14]王云, 郭素芹, 张子梅, 等.帕利哌酮缓释片治疗首发精神分裂症的疗效及安全性[J].新乡医学院学报, 2015, 32 (11) :1015-1018.[14]王云, 郭素芹, 张子梅, 等.帕利哌酮缓释片治疗首发精神分裂症的疗效及安全性[J].新乡医学院学报, 2015, 32 (11) :1015-1018.
[15]袁天懿, 秦玲, 姚明荣, 等.帕利哌酮缓释片治疗精神分裂症43例[J].医药导报, 2011, 30 (10) :1288-1290.[15]袁天懿, 秦玲, 姚明荣, 等.帕利哌酮缓释片治疗精神分裂症43例[J].医药导报, 2011, 30 (10) :1288-1290.
[16]张久平, 柯晓燕, 储康康, 等.帕利哌酮缓释片治疗儿童青少年精神分裂症的开放性研究[J].四川精神卫生, 2011, 24 (3) :159-161.[16]张久平, 柯晓燕, 储康康, 等.帕利哌酮缓释片治疗儿童青少年精神分裂症的开放性研究[J].四川精神卫生, 2011, 24 (3) :159-161.
[17]段黎明.帕利哌酮缓释片治疗儿童精神分裂症的疗效与安全性研究[J].内蒙古医学杂志, 2014, 46 (4) :391-392.[17]段黎明.帕利哌酮缓释片治疗儿童精神分裂症的疗效与安全性研究[J].内蒙古医学杂志, 2014, 46 (4) :391-392.

Relative Articles(20)

Relative Articles

[1]	Tiantian CHENG, Wensa YIN, Jia WANG, Yumei LU, Xuanyu CHEN, Shengjie NIE, Linlin LIU. Association between TMTC1 Gene Polymorphisms and Schizophrenia. Journal of Kunming Medical University, 2023, 44(10): 161-167. doi: 10.12259/j.issn.2095-610X.S20231014
[2]	Wensa YIN, Yumei LU, Jinlian TONG, shengjie NIE, Ye RUAN. Research Progress of DNA Methylation and Schizophrenia. Journal of Kunming Medical University, 2023, 44(8): 145-150. doi: 10.12259/j.issn.2095-610X.S20230811
[3]	Yandong GUO, Rudan HONG, Yanjiao WANG, Teng ZHANG, Yuemei FENG, Nishang ZHANG, Ying QIAN, Zaogai YANG, Fei MI, Jianzhong YIN. Effects of Perindopril on Intestinal Microecology in Obese Rats. Journal of Kunming Medical University, 2022, 43(11): 9-16. doi: 10.12259/j.issn.2095-610X.S20221101
[4]	Chaojie ZOU, Yikai TANG, Shuwen DU, Yuqi CHENG. Effects of Modulation of CDC42 Activity in Hippocampal Neurons on Memory and Anxiety Behaviors of Mice. Journal of Kunming Medical University, 2022, 43(11): 1-8. doi: 10.12259/j.issn.2095-610X.S20221105
[5]	Di ZENG, Han-rui SHAO, Ying-ying ZOU, Yong-hua RUAN. Research Progress of Orphan Receptor GPR88 in Related Diseases. Journal of Kunming Medical University, 2021, 42(7): 137-142. doi: 10.12259/j.issn.2095-610X.S20210723
[6]	Feng Zi Qiao , Zhang Yun Qiao , You Xu , Zhang Wen Yu , Long Qing , Teng Zhao Wei , Zeng Yong . . Journal of Kunming Medical University, 2020, 41(05): 150-153.
[7]	Gao Qing , Xie Xing , Luo Li . . Journal of Kunming Medical University, 2020, 41(09): 77-81.
[8]	Wu Jie , Zhang Yun Qiao , Teng Zhao Wei , You Xu , Liu Zi Jun , Ma Yu Han , Zhang Wen Yu , Feng Zi Qiao , Long Qing , Zeng Yong . . Journal of Kunming Medical University, 2019, 40(07): 137-141.
[9]	Liu Chang , Shen Zong Lin , Cheng Yu Qi , Xu Xiu Feng . . Journal of Kunming Medical University, 2019, 40(10): 160-164.
[10]	Jiang Hong Yan , Ran Liu Yi , Wu Gui Xia , Xu Xiu Feng , Yu Li . A Study of Correlation between NDST3 Gene Polymorphism and Schizophrenia Among Han People in Yunnan. Journal of Kunming Medical University, 2018, 39(02): 51-54.
[11]	Lin Yuan Yuan , Yuan Jing , Zeng Lei , Wei Yu Jun , Zhang Yan , Xu Li , Yang Jian Zhong . Association between Polymorphisms of rs3924999, rs35753505 in NRG1 Gene and the Efficacy of Risperidone in Patients with Schizophrenia. Journal of Kunming Medical University, 2018, 39(06): 76-81.
[12]	Chen Shan Shan , Tao Si Ming , Han Ming Hua . Clinical Observation on Treatment of Coronary Heart Disease Angina by Enough Metoprolol. Journal of Kunming Medical University, 2017, 38(11): 101-103.
[13]	Feng Guo Hua , Wei Yu Jun , Yuan Jing , Zhang Yan , Zeng Lei , Yang Jian Zhong . . Journal of Kunming Medical University, 2017, 38(05): 50-55.
[14]	Zhu Jun Yan . The Influence of Naikan Therapyon on Depression in Patients with Schizophrenia. Journal of Kunming Medical University,
[15]	Fu Zhong Yang . . Journal of Kunming Medical University,
[16]	Hou Xi . . Journal of Kunming Medical University,
[17]	Ao Lei . . Journal of Kunming Medical University,
[18]	Yan Jun Ling . . Journal of Kunming Medical University,
[19]	Hou Xi . . Journal of Kunming Medical University,
[20]	Hu Dong Hui . 阿立哌唑与利培酮治疗阿尔茨海默病性痴呆精神症状的临床对照. Journal of Kunming Medical University,